CN101904891A - Ginkgo leaf pills and preparation method thereof - Google Patents
Ginkgo leaf pills and preparation method thereof Download PDFInfo
- Publication number
- CN101904891A CN101904891A CN 201010237135 CN201010237135A CN101904891A CN 101904891 A CN101904891 A CN 101904891A CN 201010237135 CN201010237135 CN 201010237135 CN 201010237135 A CN201010237135 A CN 201010237135A CN 101904891 A CN101904891 A CN 101904891A
- Authority
- CN
- China
- Prior art keywords
- extract
- pills
- ginkgo leaf
- herb gynostemmae
- gynostemmae pentaphylli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000218628 Ginkgo Species 0.000 title claims abstract description 43
- 235000011201 Ginkgo Nutrition 0.000 title claims abstract description 43
- 235000008100 Ginkgo biloba Nutrition 0.000 title claims abstract description 43
- 239000006187 pill Substances 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000000284 extract Substances 0.000 claims abstract description 57
- 241000222336 Ganoderma Species 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 9
- 230000006837 decompression Effects 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 240000008397 Ganoderma lucidum Species 0.000 claims description 5
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 5
- 241000219071 Malvaceae Species 0.000 claims description 3
- 230000000274 adsorptive effect Effects 0.000 claims description 3
- 238000010009 beating Methods 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 22
- 239000008280 blood Substances 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 19
- 230000001603 reducing effect Effects 0.000 abstract description 11
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 230000036772 blood pressure Effects 0.000 abstract description 6
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 6
- 206010008118 cerebral infarction Diseases 0.000 abstract description 5
- 208000029078 coronary artery disease Diseases 0.000 abstract description 5
- 208000007718 Stable Angina Diseases 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 235000007756 Akebia quinata Nutrition 0.000 abstract 1
- 240000008027 Akebia quinata Species 0.000 abstract 1
- 239000009429 Ginkgo biloba extract Substances 0.000 abstract 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- -1 terpene lactones Chemical class 0.000 description 8
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000004089 microcirculation Effects 0.000 description 5
- 235000007586 terpenes Nutrition 0.000 description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 108010003541 Platelet Activating Factor Proteins 0.000 description 3
- 230000000881 depressing effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940126672 traditional medicines Drugs 0.000 description 3
- 230000008728 vascular permeability Effects 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000007333 Brain Concussion Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses ginkgo leaf pills and a preparation method thereof. The ginkgo leaf pills are prepared from a ginkgo leaf extract, a fiveleaf gynostemma herb extract and a lucid ganoderma extract through reasonable compatibility according to different characteristics of raw materials. The formula of the ginkgo leaf pills is made according to the theory of traditional Chinese medicine and essence is extracted, so that the ginkgo leaf pills can have better effects of reducing blood pressure and blood fat, promoting blood circulation, removing blood stasis and dredging collaterals, and are nontoxic and harmless to human bodies. The ginkgo leaf pills are used for treating chest obstruction, cardiodynia and apoplexia caused by blocked blood and qi, and have good curative effect on coronary disease, stable angina pectoris and cerebral infarction.
Description
Technical field
The invention belongs to field of traditional Chinese, be specifically related to a kind of ginkgo leaf pills and preparation method thereof.
Background technology
Along with the quickening of constructing well-off society speed and the raising of living standards of the people, hyperlipemia has become the powerful killer who threatens health of people, and hyperlipemia is the key factor of bringing out diseases such as coronary heart disease, arteriosclerosis, cerebral infarction, though existing various Western medicine are obtained very ten-strike in the blood fat reducing field, but side effect is obvious, is not suitable for taking for a long time.Compare with Western medicine, the active ingredient of Chinese herbs toxic and side effects is less relatively, so the research of Chinese traditional medicines depressing lipid is significant to improving level of human health.Find through investigation, there is the various active composition to have good effect for reducing fat in the natural Chinese medicine, so each developer has strengthened the research to Chinese traditional medicines depressing lipid, Chinese traditional medicines depressing lipid preparation such as gingko leaf preparation has appearred, but problems such as the gingko leaf preparation of extensive use at present all exists, and compatibility is unreasonable, the property taken into account is relatively poor, drug component single (the main pharmacodynamics composition often has only Folium Ginkgo extract), dosage are big, take often, patient dependence difference influence the clinical efficacy of medicine greatly.
Summary of the invention
The object of the present invention is to provide a kind of effect, and reduce, alleviate the ginkgo leaf pills preparation that development takes place diseases of cardiovascular and cerebrovascular systems with activating blood circulation to dissipate blood stasis and dredge the collateral, lowering blood pressure.
Solution of the present invention be based on motherland's medical science to diseases of cardiovascular and cerebrovascular systems (as hypertension, hyperlipidemia, coronary heart disease, cerebral infarction etc.) understanding of mechanism and Therapeutic Principle, achieve with reference to modern pharmacological research, from motherland's medical treasure-house, filter out that benefiting vital QI for tranquillizing is pure and impure to be let out, the natural plant of blood circulation promoting and blood stasis dispelling the meridian dredging, by the theory of Chinese medical science prescription, skim the cream off milk, make it have the enhancing antiotasis, coronary artery dilator, vessel softening, improve vascular permeability, bring high blood pressure down, triglyceride reducing and cholesterol, antiplatelet aggregation, reduce thrombotic effect, thereby reach blood pressure lowering, blood fat reducing, it is glutinous to fall blood, the effect of microcirculation improvement.
The present invention is the medicament of being made by following weight parts proportion raw material medicine:
Folium Ginkgo extract 5-15 part
Herb Gynostemmae Pentaphylli extract 3-7 part
Ganoderma extract 3-7 part
Optimum, the weight portion proportioning of each crude drug is among the present invention:
10 parts of Folium Ginkgo extract
5 parts of Herb Gynostemmae Pentaphylli extracts
5 parts of Ganoderma extracts
The preparation technology that above-mentioned each crude drug is made medicine of the present invention is:
(1) preparation of extract:
Folium Ginkgo extract: selecting the age of tree is 3～5 years, in the Semen Ginkgo greenery that pluck 6～July, adds the water making beating, obtains pressed liquor; Described pressed liquor is filtered, filtrate is crossed macroporous adsorptive resins, use ethanol elution then, the collection ethanol elution carries out concentrate drying and gets dry thing, adds ethanol in dry thing, heating and refluxing extraction 3 times, each 2～3 hours, merge extractive liquid,, decompression recycling ethanol, the extracting solution after ethanol volatilizes makes Folium Ginkgo extract after drying.
Herb Gynostemmae Pentaphylli extract: get Herb Gynostemmae Pentaphylli, the decocting that adds 6～10 times of amounts of Herb Gynostemmae Pentaphylli boils 3 times, and each 1 hour, collecting decoction, it is 1.15～1.20 that decocting liquid is concentrated into relative density, filters, and will make Herb Gynostemmae Pentaphylli extract after the filtrate drying.
Ganoderma extract: the basswood Ganoderma lucidum (Leyss. Ex Fr.) Karst. sporophore with the band spore powder is a raw material, pulverizes the back and adopts defat with petroleum ether, evaporates into no ether flavor; The powder that obtains is added alcohol heating reflux extract 3 times, each 2～3 hours, merge extractive liquid,, decompression recycling ethanol, the extracting solution after ethanol volatilizes makes Ganoderma extract after drying.
(2) preparation of ginkgo leaf pills:
Measure above-mentioned Folium Ginkgo, Herb Gynostemmae Pentaphylli and Ganoderma extract mix homogeneously by above-mentioned prescription, make evenly regular pill of size with pharmaceutically acceptable carrier.
The main component of Folium Ginkgo extract is gingkgo flavonoids and Folium Ginkgo terpene lactones.Gingkgo flavonoids mainly is to strengthen antiotasis, coronary artery dilator, vessel softening, improve vascular permeability, antiplatelet aggregation, minimizing thrombosis, triglyceride reducing (TG) and gallbladder with alcohol, the endovascular HDL-C that raises (HDL-C), thereby reaches blood pressure lowering, blood fat reducing, fall that blood is glutinous, the effect of microcirculation improvement.Reduce cholesterol levels in the blood of human body, prevent arteriosclerosis, to be short of physical strength behind the middle-aged and elderly people light activity, palpitating speed, chest pain, the effect of being significantly improved such as feel dizzy.Bring high blood pressure down by increasing vascular permeability and elasticity, blood pressure lowering effect is preferably arranged.Eliminate the deposition composition on the blood vessel wall, improve hemorheological property, promote erythrocyte deformability, reduce the blood stickiness, make blood flow unobstructed, can prevent and treat cerebral hemorrhage and cerebral infarction.The senile dementia that arteriosclerosis is caused also has certain curative effect.
Folium Ginkgo terpene lactones is optionally resisted platelet activating factor.Platelet activating factor is a kind of very strong caused platelet aggregation and a thrombosed endogenous active substance in the human body, be to bring out cardiovascular and cerebrovascular disease, particularly cause the stealthy killer of apoplexy, myocardial infarction, danger is very high, and Folium Ginkgo terpene lactones then is the jinx of platelet activating factor.
Folium Ginkgo terpene lactones and flavonoid glycoside have synergism, and expansible blood vessel, blood flow increasing improve cardiovascular and cerebrovascular circulation, under anaerobic conditions protect brain and myocardial cell.In addition, can reduce triglyceride in the blood, and improve hdl concentration.So the preparation of Folium Ginkgo extract all has comparatively favorable effects to patients such as angina pectoris, hyperlipidemia and cerebral concussion, cerebral trauma sequelas, and untoward reaction is rare, easily accept for people as blood lipid-lowering medicine.
The Herb Gynostemmae Pentaphylli extract main component is a Herb Gynostemmae Pentaphylli total glycosides, find that through pharmacological research widely it has stronger arteriosclerosis, the effect of blood fat reducing, modern pharmacology studies have shown that, Herb Gynostemmae Pentaphylli has effects such as blood fat reducing, blood pressure lowering, increase coronary artery and cerebral blood flow, defying age, strong, enhance immunity, to preventing and treating arteriosclerosis, suppressing various disease conditions such as thrombosis, hypertension, coronary heart disease, apoplexy, diabetes, obesity and have than significant curative effect.
The Ganoderma extract main component is ganoderan and ganoderma lucidum triterpene compounds.The ganoderan compounds is the contained important physiologically active ingredient of Ganoderma, be subjected to medical sci-tech worker's attention deeply, now prove: ganoderan has human body immunity improving power, improves body's hypoxia tolerance, blood sugar lowering, blood fat reducing, anti-radiation and antidotal effect.Triterpenoid such as Ganodenic acid, it once showed and can bring high blood pressure down, and reduced the platelet stickiness, and may reduce low-density lipoprotein cholesterol.Ganoderma extract is coronary artery dilator effectively, and coronary blood flow increasing improves myocardium microcirculation, strengthens the supply of myocardium oxygen and energy, therefore, myocardial ischemia is had protective effect, can be used for the treatment and the prevention of angina pectoris.To the high fat of blood patient, Ganoderma extract also can obviously reduce cholesterolemia and triglyceride, and the formation of energy prevention of arterial atherosclerotic plaque.For atherosclerotic plaque former, then have and reduce arterial wall cholesterol level, vessel softening, prevent the further effect of damage.In addition, Ganoderma extract also can improve local microcirculation, stops platelet aggregation.These effects have good preventive and therapeutic effect for polytype apoplexy.
It is raw material that the present invention selects natural plant for use, each crude drug meets the pharmaceutical control law regulation, Folium Ginkgo extract is with Herb Gynostemmae Pentaphylli and Ganoderma extract compatibility, based on Folium Ginkgo extract, assistant is with Herb Gynostemmae Pentaphylli and Ganoderma extract, utilize the comprehensive function of each crude drug, collection improves local microcirculation, enhance immunity, the anti-ageing one that is older than, can bring into play its blood pressure lowering better, blood fat reducing, the effect of activating blood circulation to dissipate blood stasis and dredge the collateral, nontoxic to human body, the present invention is to the obstructed thoracic obstruction that causes of vim and vigour, pained, apoplexy, the coronary heart disease stable angina pectoris, cerebral infarction sees that above-mentioned disease person has good curative effect.
For showing the therapeutic effect of medicine of the present invention to hyperlipidemia, the present invention is through the clinical observation of 100 routine systems.
Instructions of taking: take 0.2g (10 milligrams of the apricot yellow ketone compounds of argentiferous, 3 milligrams of Folium Ginkgo terpene lactoness, 7 milligrams of Herb Gynostemmae Pentaphylli total glycosidess, 6 milligrams of ganoderans, 3 milligrams of ganoderma lucidum triterpene compounds), day obeys once at every turn, 12 months courses of treatment.
Table 1 is taken the average concentration change of medicine front and back blood fat of the present invention
Observe 156 routine angina pectoris patients, take (take 0.2g, day clothes once at every turn) the present invention 97 routine transference cures or basic disappearance after 30 days, all there are obvious reduction by 53 routine angina pectoris attacks number of times, degree and persistent period, invalid 6 examples.Through the improvement of clinical symptoms, Electrocardiographic variation are compared observation, patient's myocardial ischemia obviously improves, the serum total cholesterol 0.60mmol/L (P＜0.05) that on average descended, the number of times of angina pectoris attacks reduces, the persistent period shortens, and onset time is many in 2 weeks of back of taking medicine.The patient takes medicine of the present invention, and that obtains significant curative effect accounts for 52%, substantially effectively accounts for 43%, and invalid accounts for 4%, and total effective rate reaches 96%.
The specific embodiment
Embodiment
(1) preparation of extract:
Folium Ginkgo extract: selecting the age of tree is 3～5 years, in the Semen Ginkgo greenery that pluck 6～July, adds the water making beating, obtains pressed liquor; Described pressed liquor is filtered, filtrate is crossed macroporous adsorptive resins, use ethanol elution then, the collection ethanol elution carries out concentrate drying and gets dry thing, in dry thing, add alcohol heating reflux and extract 3 times, each 2～3 hours, merge extractive liquid,, decompression recycling ethanol, the extracting solution after ethanol volatilizes makes Folium Ginkgo extract after drying.
Herb Gynostemmae Pentaphylli extract: get Herb Gynostemmae Pentaphylli, the decocting that adds 6～10 times of amounts of Herb Gynostemmae Pentaphylli boils 3 times, and each 1 hour, collecting decoction, it is 1.15～1.20 that decocting liquid is concentrated into relative density, filters, and will make Herb Gynostemmae Pentaphylli extract after the filtrate drying.
Ganoderma extract: the basswood Ganoderma lucidum (Leyss. Ex Fr.) Karst. sporophore with the band spore powder is a raw material, pulverizes the back and adopts defat with petroleum ether, evaporates into no ether flavor; The powder that obtains is added alcohol heating reflux extract 3 times, each 2～3 hours, merge extractive liquid,, decompression recycling ethanol, the extracting solution after ethanol volatilizes makes Ganoderma extract after drying.
(2) preparation of ginkgo leaf pills:
Take by weighing raw material by following formula ratio:
Folium Ginkgo extract 10kg, Herb Gynostemmae Pentaphylli extract 5kg, Ganoderma extract 5kg with above-mentioned Folium Ginkgo, Herb Gynostemmae Pentaphylli and Ganoderma extract mix homogeneously, makes evenly regular pill of size with pharmaceutically acceptable carrier.
Claims (3)
1. ginkgo leaf pills, it is characterized in that: this ginkgo leaf pills is the medicament of being made by following weight parts proportion raw material medicine:
Folium Ginkgo extract 5-15 part
Herb Gynostemmae Pentaphylli extract 3-7 part
Ganoderma extract 3-7 part.
2. ginkgo leaf pills according to claim 1, wherein the weight portion proportioning of each raw material is:
10 parts of Folium Ginkgo extract
5 parts of Herb Gynostemmae Pentaphylli extracts
5 parts of Ganoderma extracts.
3. prepare the method for ginkgo leaf pills as claimed in claim 1 or 2, it is characterized in that: this preparation method may further comprise the steps:
(1) preparation of extract:
Folium Ginkgo extract: selecting the age of tree is 3～5 years, in the Semen Ginkgo greenery that pluck 6～July, adds the water making beating, obtains pressed liquor; Described pressed liquor is filtered, filtrate is crossed macroporous adsorptive resins, use ethanol elution then, the collection ethanol elution carries out concentrate drying and gets dry thing, adds ethanol in dry thing, heating and refluxing extraction 3 times, each 2～3 hours, merge extractive liquid,, decompression recycling ethanol, the extracting solution after ethanol volatilizes makes Folium Ginkgo extract after drying;
Herb Gynostemmae Pentaphylli extract: get Herb Gynostemmae Pentaphylli, the decocting that adds 6～10 times of amounts of Herb Gynostemmae Pentaphylli boils 3 times, and each 1 hour, collecting decoction, it is 1.15～1.20 that decocting liquid is concentrated into relative density, filters, and will make Herb Gynostemmae Pentaphylli extract after the filtrate drying;
Ganoderma extract: the basswood Ganoderma lucidum (Leyss. Ex Fr.) Karst. sporophore with the band spore powder is a raw material, pulverizes the back and adopts defat with petroleum ether, evaporates into no ether flavor; The powder that obtains is added alcohol heating reflux extract 3 times, each 2～3 hours, merge extractive liquid,, decompression recycling ethanol, the extracting solution after ethanol volatilizes makes Ganoderma extract after drying;
(2) preparation of ginkgo leaf pills:
Measure above-mentioned Folium Ginkgo, Herb Gynostemmae Pentaphylli and Ganoderma extract mix homogeneously by above-mentioned prescription, make evenly regular pill of size with pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102371351A CN101904891B (en) | 2010-07-27 | 2010-07-27 | Ginkgo leaf pills and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102371351A CN101904891B (en) | 2010-07-27 | 2010-07-27 | Ginkgo leaf pills and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101904891A true CN101904891A (en) | 2010-12-08 |
| CN101904891B CN101904891B (en) | 2012-03-21 |
Family
ID=43260577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102371351A Active CN101904891B (en) | 2010-07-27 | 2010-07-27 | Ginkgo leaf pills and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101904891B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102630790A (en) * | 2012-05-08 | 2012-08-15 | 四川九通慧医药信息科技有限公司 | Tartary buckwheat tea prepared by Ginkgo biloba leaf and preparation process thereof |
| CN103250944A (en) * | 2012-03-08 | 2013-08-21 | 山东德圣医药科技有限公司 | Auxiliary hypolipidemic health-care food |
| CN108653722A (en) * | 2018-07-04 | 2018-10-16 | 于银行 | A kind of Chinese medicine composition, preparation method and application |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327852A (en) * | 2001-06-29 | 2001-12-26 | 成都新世纪科技有限责任公司 | Chinese medicine for treating coronary heart disease, reducing blood fat and improving sleep and its preparing process |
| CN1634537A (en) * | 2004-11-04 | 2005-07-06 | 苏州中药研究所 | Glossy ganoderma extract and preparation method and use thereof |
| CN1957958A (en) * | 2006-08-09 | 2007-05-09 | 湖南九汇现代中药有限公司 | Method for preparing extractive of ginkgo leaves |
| CN101133767A (en) * | 2006-09-01 | 2008-03-05 | 颜廷和 | Gingkgo tonic tea and preparing process thereof |
-
2010
- 2010-07-27 CN CN2010102371351A patent/CN101904891B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327852A (en) * | 2001-06-29 | 2001-12-26 | 成都新世纪科技有限责任公司 | Chinese medicine for treating coronary heart disease, reducing blood fat and improving sleep and its preparing process |
| CN1634537A (en) * | 2004-11-04 | 2005-07-06 | 苏州中药研究所 | Glossy ganoderma extract and preparation method and use thereof |
| CN1957958A (en) * | 2006-08-09 | 2007-05-09 | 湖南九汇现代中药有限公司 | Method for preparing extractive of ginkgo leaves |
| CN101133767A (en) * | 2006-09-01 | 2008-03-05 | 颜廷和 | Gingkgo tonic tea and preparing process thereof |
Non-Patent Citations (3)
| Title |
|---|
| 《中药材》 20040225 王玮等 抗运动性疲劳单味中药研究概述 第27卷, 第02期 2 * |
| 《中西医结合心脑血管病杂志》 20050630 刘春玲等 中医药防治动脉粥样硬化的实验研究进展 第3卷, 第06期 2 * |
| 《山东食品发酵》 20080620 王建伟等 我国银杏叶茶的发展现状及前景 , 第02期 2 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103250944A (en) * | 2012-03-08 | 2013-08-21 | 山东德圣医药科技有限公司 | Auxiliary hypolipidemic health-care food |
| CN102630790A (en) * | 2012-05-08 | 2012-08-15 | 四川九通慧医药信息科技有限公司 | Tartary buckwheat tea prepared by Ginkgo biloba leaf and preparation process thereof |
| CN102630790B (en) * | 2012-05-08 | 2015-02-11 | 四川九通慧医药信息科技有限公司 | Tartary buckwheat tea prepared by Ginkgo biloba leaf and preparation process thereof |
| CN108653722A (en) * | 2018-07-04 | 2018-10-16 | 于银行 | A kind of Chinese medicine composition, preparation method and application |
| CN108653722B (en) * | 2018-07-04 | 2021-12-24 | 穆棱市晟宇生物科技有限公司 | Traditional Chinese medicine composition, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101904891B (en) | 2012-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103493941B (en) | A kind of Weight-reducing health-care tea and preparation method thereof | |
| CN1931261B (en) | Blood pressure and blood lipid lowering capsule and its preparation process | |
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN103330119A (en) | Health-care food for accessorily reducing blood fat | |
| CN101518595A (en) | Medical composition with functions of lowering lipid, reducing fat and oxidation resistance and preparation method thereof | |
| CN101904891B (en) | Ginkgo leaf pills and preparation method thereof | |
| CN100333750C (en) | Chinese medicinal preparation for treating qi obstruction in chest and heart palpitation and its preparation process | |
| CN101732491A (en) | Medicament for treating hypertension, hyperlipoidemia, high blood viscosity and anti-aging | |
| CN102640825B (en) | Lipid-lowering tea for regulating blood lipid | |
| CN106310023A (en) | Drug for treating small cell lung cancer, and preparation method and application thereof | |
| CN102920807A (en) | Herb tea for lowering blood pressure | |
| CN103182008A (en) | Preparation method for traditional Chinese medicine used for stabilizing and reducing blood pressure | |
| CN103652059B (en) | The formula of bagged medicine tea and preparation method | |
| CN102552410B (en) | Preparation method of medicine for treating hypertension disease | |
| CN107648335B (en) | Traditional Chinese medicine composition for regulating atherosclerosis autophagy and apoptosis and preparation method thereof | |
| CN106138831A (en) | A kind of Chinese medicine composition treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN102266481B (en) | Chinese medicinal preparation for treating chronic cerebral circulation insufficiency | |
| CN103585366A (en) | Medicine for treating ischemic hyperlipidemia and preparation method thereof | |
| CN103432200B (en) | A kind of medicine for the treatment of Orthopeadic Surgery disease | |
| CN108420842A (en) | A kind of sowthistle-leaf ixeris seedling preparation of antigout effect | |
| CN104398677A (en) | Compound composition of tartary buckwheat general flavone and gynostemma pentaphylla total saponin | |
| CN105663224A (en) | Composition for treating cardiovascular and cerebrovascular diseases and preparation thereof | |
| CN106309616A (en) | Medicine with hypolipidemic effect | |
| CN1935183A (en) | Chinese medicine compound preparation and its preparing method | |
| CN103784489B (en) | A kind of Radix Aucklandiae extract and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: WUXI HONGTAI INVESTMENT CO., LTD. Free format text: FORMER OWNER: CHENGDU TIANYU UNION MEDICAL TECHNOLOGY CO., LTD. Effective date: 20111221 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Junxian Inventor after: Dan Zhen Inventor after: Shi Weiwei Inventor before: Wang Junxian Inventor before: Tang Ping |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG JUNXIAN TANG PING TO: WANG JUNXIAN DAN ZHEN SHI WEIWEI Free format text: CORRECT: ADDRESS; FROM: 610041 CHENGDU, SICHUAN PROVINCE TO: 241031 WUXI, JIANGSU PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20111221 Address after: 241031 Jiangsu province Wuxi Wu'ai Road No. 18 room B705 Applicant after: Chendu Tianyu Alliance Medicine Science and Technology Co., Ltd. Address before: 610041, building 501, Room 502, building 6, No. nine Hing Road, Chengdu hi tech Development Zone, Sichuan, Applicant before: Chengdu Tianyv Union Medical Technology Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: CHENGDU TIANYU UNION MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: WUXI HONGTAI INVESTMENT CO., LTD. Effective date: 20111229 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 241031 WUXI, JIANGSU PROVINCE TO: CHENGDU, SICHUAN PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20111229 Address after: C501, Room 502, building 6, No. nine Hing Road, Chengdu hi tech Development Zone, Sichuan, China Applicant after: Chengdu Tianyv Union Medical Technology Co., Ltd. Address before: 241031 Jiangsu province Wuxi Wu'ai Road No. 18 room B705 Applicant before: Chendu Tianyu Alliance Medicine Science and Technology Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180709 Address after: No. 5, Xiang Zhang Road, new economic development zone, Meishan, Sichuan Patentee after: Sichuan Tak Feng Pharmaceutical Co., Ltd. Address before: C501, Room 502, building 6, No. nine Hing Road, Chengdu hi tech Development Zone, Sichuan, China Patentee before: Chengdu Tianyv Union Medical Technology Co., Ltd. |
|
| TR01 | Transfer of patent right |